A proof of concept of the electronic detection of two anabolic steroids, stanozolol (Stz) and methylboldenone (MB), was carried out using two specific antibodies and arrays of carbon nanotube field-effect transistors (CNTFETs). Antibodies specific for Stz and MB were prepared and immobilized on the carbon nanotubes (CNTs) using two different approaches: direct noncovalent bonding of antibodies to the devices and bonding the antibodies covalently to a polymer previously attached to the CNTFETs. The results indicated that CNTFETs bonded to specific antibodies covalently or noncovalently are able to detect the presence of steroids. Statistically significant changes in the threshold voltage and drain current were registered in the transistors, allowing the steroids to be recognized. On the other hand, it was determined that the specific antibodies do not detect other steroids other than Stz and MB, such as nandrolone (ND) because, in this case, statistically significant changes in the transistors were not detected. The polymer prevents the aggregation of antibodies on the electrodes and decreases the transistor hysteresis. Nevertheless, it is not able to avoid the nonspecific adsorption of streptavidin, meaning that nonspecific adsorption on CNTs remains a problem and that this methodology is only useful for purified samples. Regarding the detection mechanism, in addition to charge transfer, Schottky barrier, SB, modification, and scattering potential reported by other authors, an electron/hole trapping mechanism leading to hysteresis modification has been determined. The presence of polymer seems to hinder the modulation of the electrode-CNT contact.

Download full-text PDF

Source
http://dx.doi.org/10.1021/nn901547bDOI Listing

Publication Analysis

Top Keywords

specific antibodies
12
carbon nanotube
8
nanotube field-effect
8
field-effect transistors
8
bonding antibodies
8
antibodies covalently
8
statistically changes
8
nonspecific adsorption
8
antibodies
7
electronic anabolic
4

Similar Publications

Structural and Functional Glycosylation of the Abdala COVID-19 Vaccine.

Glycobiology

January 2025

Department of Biochemistry, Dorothy Crowfoot Hodgkin Building, University of Oxford, South Parks Road, OX1 3QU, United Kingdom.

Abdala is a COVID-19 vaccine produced in Pichia pastoris and is based on the receptor-binding domain (RBD) of the SARS-CoV-2 spike. Abdala is currently approved for use in multiple countries with clinical trials confirming its safety and efficacy in preventing severe illness and death. Although P.

View Article and Find Full Text PDF

Seroprevalence of specific antibodies to Treponema pallidum in blood donors with DNA confirmation of seropositivity.

Cell Mol Biol (Noisy-le-grand)

January 2025

Swedish Board Member of General Surgery, Kurdistan Higher Council of Medical Specialties, Erbil, Iraq.

The rising global incidence of syphilis underscores the risk of transmission through blood transfusions. Treponema pallidum, the pathogen responsible for syphilis, represents a major public health challenge. Accurate detection is essential for controlling the disease, particularly in asymptomatic blood donors.

View Article and Find Full Text PDF

[Characteristics of immune response induced by mucosal immunization with recombinant adenovirus of Mycobacterium tuberculosis phosphodiesterase].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

January 2025

Department of Microbiology and Pathogenic Biology, Air Force Military Medical University, Xi'an 710032, China. *Corresponding authors, E-mail:

Objective The prevalence of drug-resistant Mycobacterium tuberculosis (Mtb) strains is exacerbating the global burden of tuberculosis (TB), highlighting the urgent need for new treatment strategies for TB. Methods The recombinant adenovirus vaccine expressing cyclic di-adenosine monophosphate (c-di-AMP) phosphodiesterase B (CnpB) (rAd-CnpB), was administered to normal mice via mucosal immunization, either alone or in combination with drug therapy, to treat Mtb respiratory infections in mice.Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of antibodies in serum and bronchoalveolar lavage fluid (BALF).

View Article and Find Full Text PDF

Antibody-mediated rejection (AMR) remains a major complication after solid organ transplantation (SOT). Current treatment options are inefficient and result in drastic impairment of the general immunity. To selectively eliminate responsible alloreactive B cells characterized by anti-donor-HLA B-cell receptors (BCRs), we generated T cells overcoming rejection by antibodies (CORA-Ts) engineered with a novel chimeric receptor comprising a truncated donor-HLA molecule as antigen recognition domain.

View Article and Find Full Text PDF

Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study.

BMC Nephrol

January 2025

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Key Laboratory of Organ Transplantation, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Huazhong University of Science and Technology, Ministry of Education, Chinese Academy of Medical Sciences, Wuhan, China.

Background: Effective treatment of late antibody-mediated rejection (late AMR) is still an unmet medical need. Clearing donor-specific antibody (DSA) and preventing its rebound is the ideal goal of treatment.

Methods: We have summarized the clinical data from seven patients with late or chronic active AMR after renal transplantation who received daratumumab (Dara)-based treatment first (Phase 1) and then tocilizumab (TCZ) therapy (Phase 2).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!